Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 6Completed 5Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 473Carcinoma, Non-Small-Cell Lung 447Breast Neoplasms 331Neoplasm Metastasis 242Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 148Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 123Carcinoma, Renal Cell 112Squamous Cell Carcinoma of Head and Neck 110Leukemia, Lymphocytic, Chronic, B-Cell 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 87Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 74Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Metastatic Castration-Resistant Prostate Cancer × Clear all
NCT03137758 2020-03-09

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Pellficure Pharmaceuticals, Inc

Phase 1 Terminated
12 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡